BioCryst Pharmaceuticals Welcomes Charlie Gayer as New CEO

Leadership Transition at BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. today confirmed that Jon Stonehouse, the current president and chief executive officer, plans to retire soon, marking the end of an era for the company. As Stonehouse steps down on December 31, 2025, the board has recognized the potential of Charlie Gayer, who currently serves as chief commercial officer, to transition into the role of president effective August 1, 2025, and chief executive officer from January 1, 2026.

Expectations from Charlie Gayer

Gayer's appointment comes on the heels of his successful tenure at BioCryst, where he has significantly impacted the commercial landscape with the launch of ORLADEYO (berotralstat), the first oral prophylactic therapy for hereditary angioedema. Under Gayer's leadership, the company anticipates peak sales for this therapy to reach $1 billion, showcasing his capability to guide BioCryst into its next level of growth.

Successful Drug Launch

Having led the charge on ORLADEYO, Gayer's strong commercial background positions him well for the role of CEO. The launch has not only been a financial success but has also contributed to a paradigm shift in how patients experiencing hereditary angioedema manage their condition. Furthermore, Gayer has played a key role in shaping the company’s strategies, including plans to streamline its operational focus regarding European business ventures.

Recognition of Jon Stonehouse's Contributions

Nancy Hutson, chair of the board, expressed her gratitude for Stonehouse's contributions, stating that he built BioCryst into a profitable firm with a promising future. She noted Gayer's exceptional qualifications during the succession planning process, highlighting his ability to leverage past successes to further enhance the company’s mission to deliver groundbreaking therapies for patients.

Charlie Gayer’s Vision for BioCryst

Gayer acknowledged Stonehouse's impact on fostering a patient-first culture at BioCryst, which has been pivotal to the company's growth. He expressed his excitement about steering the company into its next chapter and reaffirmed his commitment to continuing the legacy established by Stonehouse.

Background and Qualified Experience of Charlie Gayer

Gayer joined BioCryst in 2015, initially as vice president of global strategic marketing, and rapidly advanced to CCO by January 2020. His diverse experience spans over several leadership roles at prestigious firms within the biopharmaceutical sector. Prior to BioCryst, he held significant positions at Talecris Biotherapeutics and Grifols, leading influential marketing strategies focused on rare disease categories, particularly in the treatment of alpha-1 antitrypsin deficiency.

Educational Foundations

Gayer's credentials include a B.A. in Politics from Princeton University and an M.B.A. from Duke University's Fuqua School of Business, underscoring his robust academic foundation that complements his extensive industry experience.

About BioCryst Pharmaceuticals

BioCryst is dedicated to developing innovative treatments for rare diseases using expertise in structure-guided drug design. The firm has successfully commercialized ORLADEYO and is working to advance its pipeline, which includes a variety of therapies. BioCryst remains committed to enhancing the lives of patients inheriting challenging conditions and focuses on delivering first-in-class and best-in-class drug options.

Frequently Asked Questions

Who is Charlie Gayer?

Charlie Gayer is the new chief executive officer of BioCryst Pharmaceuticals, succeeding Jon Stonehouse upon his retirement.

What role did Jon Stonehouse play at BioCryst Pharmaceuticals?

Jon Stonehouse served as the president and chief executive officer, leading the company through significant growth and the commercialization of key therapies such as ORLADEYO.

What is ORLADEYO?

ORLADEYO (berotralstat) is the first oral prophylactic therapy developed for patients with hereditary angioedema, and it has achieved impressive revenue milestones under Gayer's leadership.

What are BioCryst's future plans?

BioCryst aims to expand its therapy pipeline and enhance patient accessibility to innovative treatments, leveraging Gayer's experience and leadership.

How did Gayer's career lead to this position?

Gayer has a strong background in commercial leadership within the biopharmaceutical industry, having successfully launched multiple therapies and shaped strategic initiatives at BioCryst.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.